Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
$63.8316
-4.08(-6.4%)
as of July 17, 2026
Try our APIs with
free plan!
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prev. Close
63.8316
Open
59.7496
High
64.8075
Low
59.5761
52 wk Range
26.27-67.53
Market Cap
4 920 M
P/E Ratio
70.2747
Shares Outstanding
46 303 K
Revenue
754 M
EPS
0.27
Beta
0.07
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kiniksa Pharmaceuticals Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 754 M
- EBITDA: 94 893 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kiniksa Pharmaceuticals Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-05
- EPS/Forecast: 0.324
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
Eli Lilly LLY announced that it has entered into a definitive agreement to acquire New York-based clinical-stage biotech AtaiBeckley ATAI for an initial upfront payment of $2.8 billion. Shares of ATA...
UnitedHealth Tops Q2 Earnings on Cost Control, Raises '26 Outlook
UnitedHealth Group Incorporated UNH reported second-quarter 2026 adjusted earnings per share (EPS) of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year...
ATAI Stock Soars on Reports of Potential Acquisition by Eli Lilly
Shares of clinical-stage company AtaiBeckley ATAI surged 63.3% in after-hours trading on Wednesday after a Bloomberg report stated, citing people familiar with the matter, that pharma bigwig Eli Lilly...
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca AZN announced that it has entered into an exclusive license agreement with China-based pharmaceutical company Dizal Pharmaceutical to acquire worldwide rights to develop and commercialize ...
Get Kiniksa Pharmaceuticals Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
